Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

IL-1 Transcriptional Responses to Lipopolysaccharides Are Regulated by a Complex of RNA Binding Proteins.

Shi L, Song L, Maurer K, Dou Y, Patel VR, Su C, Leonard ME, Lu S, Hodge KM, Torres A, Chesi A, Grant SFA, Wells AD, Zhang Z, Petri MA, Sullivan KE.

J Immunol. 2020 Jan 17. pii: ji1900650. doi: 10.4049/jimmunol.1900650. [Epub ahead of print]

PMID:
31953354
2.

Autoantibody clustering of lupus-associated pulmonary hypertension.

Mizus M, Li J, Goldman D, Petri MA.

Lupus Sci Med. 2019 Dec 2;6(1):e000356. doi: 10.1136/lupus-2019-000356. eCollection 2019.

3.

Development of a systemic lupus erythematosus cardiovascular risk equation.

Petri MA, Barr E, Magder LS.

Lupus Sci Med. 2019 Oct 10;6(1):e000346. doi: 10.1136/lupus-2019-000346. eCollection 2019.

4.

SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus.

Smith MA, Henault J, Karnell JL, Parker ML, Riggs JM, Sinibaldi D, Taylor DK, Ettinger R, Grant EP, Sanjuan MA, Kolbeck R, Petri MA, Casey KA.

Sci Rep. 2019 Oct 8;9(1):14433. doi: 10.1038/s41598-019-50231-y.

5.

Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Oct;20(10):1404. doi: 10.1038/s41590-019-0473-3.

PMID:
31409923
6.

Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery.

Thomas DE, Lyons JS, Greene BS, Petri MA.

Lupus Sci Med. 2019 Jun 16;6(1):e000335. doi: 10.1136/lupus-2019-000335. eCollection 2019.

7.

The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17. Erratum in: Nat Immunol. 2019 Aug 13;:.

8.

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE.

Petri MA, Conklin J, O'Malley T, Dervieux T.

Lupus Sci Med. 2019 Mar 30;6(1):e000318. doi: 10.1136/lupus-2019-000318. eCollection 2019.

9.
10.

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort.

Giannakou I, Chatzidionysiou K, Magder LS, Györi N, van Vollenhoven R, Petri MA.

Lupus Sci Med. 2018 Nov 2;5(1):e000287. doi: 10.1136/lupus-2018-000287. eCollection 2018.

11.

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW.

Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Erratum in: Lancet. 2018 Aug 11;392(10146):476.

PMID:
30043749
12.

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Merrill JT, Petri MA, Buyon J, Ramsey-Goldman R, Kalunian K, Putterman C, Conklin J, Furie RA, Dervieux T.

Lupus Sci Med. 2018 May 23;5(1):e000263. doi: 10.1136/lupus-2018-000263. eCollection 2018.

13.

Overall Downregulation of mRNAs and Enrichment of H3K4me3 Change Near Genome-Wide Association Study Signals in Systemic Lupus Erythematosus: Cell-Specific Effects.

Zhang Z, Shi L, Song L, Maurer K, Petri MA, Sullivan KE.

Front Immunol. 2018 Mar 13;9:497. doi: 10.3389/fimmu.2018.00497. eCollection 2018.

14.

Associates and predictors of pleurisy or pericarditis in SLE.

Ryu S, Fu W, Petri MA.

Lupus Sci Med. 2017 Oct 23;4(1):e000221. doi: 10.1136/lupus-2017-000221. eCollection 2017.

15.

Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Pejchinovski M, Siwy J, Mullen W, Mischak H, Petri MA, Burkly LC, Wei R.

Lupus. 2018 Jan;27(1):6-16. doi: 10.1177/0961203317707827. Epub 2017 May 5.

16.

Hydroxychloroquine-Induced Erythema Multiforme.

Abou Assalie N, Durcan R, Durcan L, Petri MA.

J Clin Rheumatol. 2017 Mar;23(2):127-128. doi: 10.1097/RHU.0000000000000417. No abstract available.

17.

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group.

Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856.

18.
19.

H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus.

Zhang Z, Shi L, Dawany N, Kelsen J, Petri MA, Sullivan KE.

Clin Epigenetics. 2016 Feb 2;8:14. doi: 10.1186/s13148-016-0179-4. eCollection 2016.

20.

Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.

Deng Y, Zhao J, Sakurai D, Sestak AL, Osadchiy V, Langefeld CD, Kaufman KM, Kelly JA, James JA, Petri MA, Bae SC, Alarcón-Riquelme ME, Alarcón GS, Anaya JM, Criswell LA, Freedman BI, Kamen DL, Gilkeson GS, Jacob CO, Merrill JT, Gaffney PM, Sivils KM, Niewold TB, Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Boackle SA, Vilá LM, Sohn II, Lee S, Chang DM, Song YW, Vyse TJ, Harley JB, Brown EE, Edberg JC, Kimberly RP, Cantor RM, Hahn BH, Grossman JM, Tsao BP.

Ann Rheum Dis. 2016 Nov;75(11):2007-2013. doi: 10.1136/annrheumdis-2015-208441. Epub 2016 Jan 18.

21.

Monocyte enhancers are highly altered in systemic lupus erythematosus.

Shi L, Zhang Z, Song L, Leung YT, Petri MA, Sullivan KE.

Epigenomics. 2015;7(6):921-35. doi: 10.2217/epi.15.47. Epub 2015 Oct 7.

22.

Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus.

Zhao J, Wu H, Langefeld CD, Kaufman KM, Kelly JA, Bae SC; Marta E. Alarcón-Riquelme for the BIOLUPUS and GENLES networks, Alarcón GS, Anaya JM, Criswell LA, Freedman BI, Kamen DL, Gilkeson GS, Jacob CO, James JA, Merrill JT, Gaffney PM, Sivils KM, Niewold TB, Petri MA, Song ST, Jeong HJ, Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Boackle SA, Vilá LM, Chang DM, Song YW, Vyse TJ, Harley JB, Brown EE, Edberg JC, Kimberly RP, Hahn BH, Grossman JM, Tsao BP, La Cava A.

Clin Immunol. 2015 Dec;161(2):157-62. doi: 10.1016/j.clim.2015.09.007. Epub 2015 Sep 16.

23.

Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study.

Martins M, Williams AH, Comeau M, Marion M, Ziegler JT, Freedman BI, Merrill JT, Glenn SB, Kelly JA, Sivils KM, James JA, Guthridge JM, Alarcón-Riquelme ME, Bae SC, Kim JH, Kim D, Anaya JM, Boackle SA, Criswell LA, Kimberly RP, Alarcón GS, Brown EE, Vilá LM, Petri MA, Ramsey-Goldman R, Niewold TB, Tsao BP, Gilkeson GS, Kamen DL, Jacob CO, Stevens AM, Gaffney PM, Harley JB, Langefeld CD, Fesel C.

Genes Immun. 2015 Mar;16(2):142-50. doi: 10.1038/gene.2014.73. Epub 2015 Jan 8.

24.

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.

Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Lupus Sci Med. 2014 Jun 26;1(1):e000031. doi: 10.1136/lupus-2014-000031. eCollection 2014.

25.

Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.

Zhao J, Giles BM, Taylor RL, Yette GA, Lough KM, Ng HL, Abraham LJ, Wu H, Kelly JA, Glenn SB, Adler AJ, Williams AH, Comeau ME, Ziegler JT, Marion M, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Alarcón GS, Anaya JM, Bae SC, Kim D, Lee HS, Criswell LA, Freedman BI, Gilkeson GS, Guthridge JM, Jacob CO, James JA, Kamen DL, Merrill JT, Sivils KM, Niewold TB, Petri MA, Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Vilá LM, Vyse TJ, Kaufman KM, Harley JB, Langefeld CD, Gaffney PM, Brown EE, Edberg JC, Kimberly RP, Ulgiati D, Tsao BP, Boackle SA.

Ann Rheum Dis. 2016 Jan;75(1):242-52. doi: 10.1136/annrheumdis-2014-205584. Epub 2014 Sep 1.

26.

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study.

Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19.

PMID:
24748629
27.

Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription.

Guthridge JM, Lu R, Sun H, Sun C, Wiley GB, Dominguez N, Macwana SR, Lessard CJ, Kim-Howard X, Cobb BL, Kaufman KM, Kelly JA, Langefeld CD, Adler AJ, Harley IT, Merrill JT, Gilkeson GS, Kamen DL, Niewold TB, Brown EE, Edberg JC, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM, Kimberly RP, Freedman BI, Stevens AM, Boackle SA, Criswell LA, Vyse TJ, Behrens TW, Jacob CO, Alarcón-Riquelme ME, Sivils KL, Choi J, Joo YB, Bang SY, Lee HS, Bae SC, Shen N, Qian X, Tsao BP, Scofield RH, Harley JB, Webb CF, Wakeland EK, James JA, Nath SK, Graham RR, Gaffney PM.

Am J Hum Genet. 2014 Apr 3;94(4):586-98. doi: 10.1016/j.ajhg.2014.03.008.

28.

Oral candidiasis in systemic lupus erythematosus.

Fangtham M, Magder LS, Petri MA.

Lupus. 2014 Jun;23(7):684-90. doi: 10.1177/0961203314525247. Epub 2014 Mar 5.

PMID:
24598219
29.

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW.

Arthritis Rheumatol. 2014 Feb;66(2):480. doi: 10.1002/art.38251. No abstract available.

30.

Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses.

Li X, Wu J, Ptacek T, Redden DT, Brown EE, Alarcón GS, Ramsey-Goldman R, Petri MA, Reveille JD, Kaslow RA, Kimberly RP, Edberg JC.

Sci Transl Med. 2013 Dec 18;5(216):216ra175. doi: 10.1126/scitranslmed.3007097.

31.

The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary.

Pons-Estel GJ, Wojdyla D, McGwin G Jr, Magder LS, Petri MA, Pons-Estel BA; Grupo Latino Americano De Estudio del Lupus (GLADEL), Alarcón GS; LUMINA cohort.

Lupus. 2014;23(1):3-9. doi: 10.1177/0961203313512883. Epub 2013 Nov 27.

PMID:
24285098
32.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

33.

Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression.

Sakurai D, Zhao J, Deng Y, Kelly JA, Brown EE, Harley JB, Bae SC, Alarcόn-Riquelme ME; BIOLUPUS and GENLES networks, Edberg JC, Kimberly RP, Ramsey-Goldman R, Petri MA, Reveille JD, Vilá LM, Alarcón GS, Kaufman KM, Vyse TJ, Jacob CO, Gaffney PM, Sivils KM, James JA, Kamen DL, Gilkeson GS, Niewold TB, Merrill JT, Scofield RH, Criswell LA, Stevens AM, Boackle SA, Kim JH, Choi J, Pons-Estel BA; Argentine Collaborative Group, Freedman BI, Anaya JM, Martin J, Yu CY, Chang DM, Song YW, Langefeld CD, Chen W, Grossman JM, Cantor RM, Hahn BH, Tsao BP.

PLoS Genet. 2013;9(10):e1003870. doi: 10.1371/journal.pgen.1003870. Epub 2013 Oct 10.

34.

PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes.

Namjou B, Kim-Howard X, Sun C, Adler A, Chung SA, Kaufman KM, Kelly JA, Glenn SB, Guthridge JM, Scofield RH, Kimberly RP, Brown EE, Alarcón GS, Edberg JC, Kim JH, Choi J, Ramsey-Goldman R, Petri MA, Reveille JD, Vilá LM, Boackle SA, Freedman BI, Tsao BP, Langefeld CD, Vyse TJ, Jacob CO, Pons-Estel B; Argentine Collaborative Group, Niewold TB, Moser Sivils KL, Merrill JT, Anaya JM, Gilkeson GS, Gaffney PM, Bae SC, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Harley JB, Criswell LA, James JA, Nath SK.

PLoS One. 2013 Aug 7;8(8):e69404. doi: 10.1371/journal.pone.0069404. eCollection 2013.

35.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

36.

Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry.

Ramos PS, Oates JC, Kamen DL, Williams AH, Gaffney PM, Kelly JA, Kaufman KM, Kimberly RP, Niewold TB, Jacob CO, Tsao BP, Alarcón GS, Brown EE, Edberg JC, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM, James JA, Guthridge JM, Merrill JT, Boackle SA, Freedman BI, Scofield RH, Stevens AM, Vyse TJ, Criswell LA, Moser KL, Alarcón-Riquelme ME, Langefeld CD, Harley JB, Gilkeson GS.

J Rheumatol. 2013 Jun;40(6):842-9. doi: 10.3899/jrheum.120989. Epub 2013 May 1. Erratum in: J Rheumatol. 2013 Jul;40(7):1240.

37.

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.

Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE; BLISS-52 and -76 Study Groups.

Ann Rheum Dis. 2014 May;73(5):838-44. doi: 10.1136/annrheumdis-2012-202865. Epub 2013 Mar 22.

38.

MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus.

Deng Y, Zhao J, Sakurai D, Kaufman KM, Edberg JC, Kimberly RP, Kamen DL, Gilkeson GS, Jacob CO, Scofield RH, Langefeld CD, Kelly JA, Ramsey-Goldman R, Petri MA, Reveille JD, Vilá LM, Alarcón GS, Vyse TJ, Pons-Estel BA; Argentine Collaborative Group, Freedman BI, Gaffney PM, Sivils KM, James JA, Gregersen PK, Anaya JM, Niewold TB, Merrill JT, Criswell LA, Stevens AM, Boackle SA, Cantor RM, Chen W, Grossman JM, Hahn BH, Harley JB, Alarcόn-Riquelme ME; BIOLUPUS and GENLES networks, Brown EE, Tsao BP.

PLoS Genet. 2013;9(2):e1003336. doi: 10.1371/journal.pgen.1003336. Epub 2013 Feb 28.

39.

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C.

Ann Rheum Dis. 2014 Jan;73(1):183-90. doi: 10.1136/annrheumdis-2012-202760. Epub 2013 Jan 12.

40.

Lymphoma risk in systemic lupus: effects of disease activity versus treatment.

Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived O, Petri MA, Jacobsen S, Manzi S, Ginzler EM, Isenberg D, Rahman A, Gordon C, Ruiz-Irastorza G, Yelin E, Bae SC, Wallace DJ, Peschken CA, Dooley MA, Edworthy SM, Aranow C, Kamen DL, Romero-Diaz J, Askanase A, Witte T, Barr SG, Criswell LA, Sturfelt GK, Blanco I, Feldman CH, Dreyer L, Patel NM, St Pierre Y, Clarke AE.

Ann Rheum Dis. 2014 Jan;73(1):138-42. doi: 10.1136/annrheumdis-2012-202099. Epub 2013 Jan 8.

41.

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups.

Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4.

PMID:
23213069
42.

Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups.

Kaufman KM, Zhao J, Kelly JA, Hughes T, Adler A, Sanchez E, Ojwang JO, Langefeld CD, Ziegler JT, Williams AH, Comeau ME, Marion MC, Glenn SB, Cantor RM, Grossman JM, Hahn BH, Song YW, Yu CY, James JA, Guthridge JM, Brown EE, Alarcón GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri MA, Reveille JD, Vilá LM, Anaya JM, Boackle SA, Stevens AM, Freedman BI, Criswell LA, Pons Estel BA; Argentine Collaborative Group, Lee JH, Lee JS, Chang DM, Scofield RH, Gilkeson GS, Merrill JT, Niewold TB, Vyse TJ, Bae SC, Alarcón-Riquelme ME; BIOLUPUS network, Jacob CO, Moser Sivils K, Gaffney PM, Harley JB, Sawalha AH, Tsao BP.

Ann Rheum Dis. 2013 Mar;72(3):437-44. doi: 10.1136/annrheumdis-2012-201851. Epub 2012 Aug 17.

43.

Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus.

Adrianto I, Wang S, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, Glenn SB, Williams AH, Ziegler JT, Comeau ME, Marion MC, Wakeland BE, Liang C, Kaufman KM, Guthridge JM, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Alarcón GS, Anaya JM, Bae SC, Kim JH, Joo YB, Boackle SA, Brown EE, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martín J, Merrill JT, Niewold TB, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Harley JB, Wakeland EK, Moser KL, Montgomery CG, Gaffney PM.

Arthritis Rheum. 2012 Nov;64(11):3695-705. doi: 10.1002/art.34642.

44.

Genetic risk factors for thrombosis in systemic lupus erythematosus.

Kaiser R, Li Y, Chang M, Catanese J, Begovich AB, Brown EE, Edberg JC, McGwin G Jr, Alarcón GS, Ramsey-Goldman R, Reveille JD, Vilá LM, Petri MA, Kimberly RP, Taylor KE, Criswell LA.

J Rheumatol. 2012 Aug;39(8):1603-10. doi: 10.3899/jrheum.111451. Epub 2012 Jun 15.

45.

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups.

Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.

46.

A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus.

Wang S, Adrianto I, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, Glenn SB, Williams AH, Ziegler JT, Comeau ME, Marion MC, Wakeland BE, Liang C, Kaufman KM, Guthridge JM, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Alarcón GS, Anaya JM, Bae SC, Kim JH, Joo YB, Boackle SA, Brown EE, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Harley JB, Wakeland EK, Moser KL, Montgomery CG, Gaffney PM.

Genes Immun. 2012 Jul;13(5):380-7. doi: 10.1038/gene.2012.6. Epub 2012 Apr 5.

47.

Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study.

Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, Adler AJ, Li H, Rasmussen A, Williams AH, Ziegler J, Comeau ME, Marion M, Wakeland BE, Liang C, Ramos PS, Grundahl KM, Gallant CJ, Alarcón-Riquelme ME, Alarcón GS, Anaya JM, Bae SC, Boackle SA, Brown EE, Chang DM, Cho SK, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Kim JH, Martin J, Merrill JT, Niewold TB, Park SY, Petri MA, Pons-Estel BA, Ramsey-Goldman R, Reveille JD, Scofield RH, Song YW, Stevens AM, Tsao BP, Vila LM, Vyse TJ, Yu CY, Guthridge JM, Kaufman KM, Harley JB, Wakeland EK, Langefeld CD, Gaffney PM, Montgomery CG, Moser KL; BIOLUPUS Network; GENLES Network.

Am J Hum Genet. 2012 Apr 6;90(4):648-60. doi: 10.1016/j.ajhg.2012.02.023. Epub 2012 Mar 29.

48.

Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis.

Fairweather D, Petri MA, Coronado MJ, Cooper LT.

Expert Rev Clin Immunol. 2012 Mar;8(3):269-84. doi: 10.1586/eci.12.10. Review.

49.

Differences between male and female systemic lupus erythematosus in a multiethnic population.

Tan TC, Fang H, Magder LS, Petri MA.

J Rheumatol. 2012 Apr;39(4):759-69. doi: 10.3899/jrheum.111061. Epub 2012 Mar 1.

50.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.

Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.

Supplemental Content

Loading ...
Support Center